News from the EAN Congress

Posted in Courses & Conferences on 27th Jun 2018

 

Conference details: June 16-19, 2018, Lisbon, Portugal
Report by: Dr Birgit Kofler, European Academy of Neurology – Press Office
Conflict of interest statement: None declared
Published online: 27/6/18


JUNE 19, 2018

Parkinson’s and multiple sclerosis: health and financial impacts for family caregivers frequently underestimated

Caring for relatives who suffer from neurological diseases such as Parkinson’s and multiple sclerosis also has health and financial implications for related caregivers. But the burden on individuals is not fully understood. This was the conclusion drawn by two studies presented at the Congress of the European Academy of Neurology in Lisbon.

Full article –> here

 

Effects of deep brain stimulation treatment on the long-term course of Parkinson’s disease

Chronic subthalamic deep brain stimulation (DBS) is associated with a decreased risk for recurrent falls and delays the onset of psychosis in patients with Parkinson’s disease. However, DBS did not affect the development of dementia and had no influence as to when a person had to be placed in a nursing home. These are the results of a comparative long-term observational study presented at the Congress of the European Academy of Neurology in Lisbon.

Full article –> here

 

European Academy of Neurology: Franz Fazekas succeeds Günther Deuschl as president

After four years at the helm of the European Academy of Neurology, Prof Günther Deuschl is passing on the mantle of President to the Austrian neurologist Prof Franz Fazekas.

Full article –> here

 

JUNE 18, 2018

Brain disorders and treatment gaps: non-treatment carries the greatest cost burden

Up to eight out of ten patients with a brain disorder remain untreated or inadequately treated. But what is the best practice – and above all, most cost effective – healthcare interventions to bridge the treatment gap? This was the focus of the European Brain Council’s study entitled The Value of Treatment which was discussed at the Congress of the European Academy of Neurology in Lisbon.

Full article –> here

 

Coma research: Reliable assessment and improvement of consciousness disorders after serious brain injuries

To diagnose patients with severe brain injuries reliably, their state of consciousness has to be evaluated several times with suitable tools. A new stimulation method increases the hope that disorders of consciousness can be improved according to Prof Steven Laureys who spoke at the Congress of the European Academy of Neurology in Lisbon.

Full article –> here

 

Thrombectomy in acute stroke therapy: Feasible for very old patients, but not without risks

The mechanical removal of blood clots in acute stroke is highly effective but not suitable for all patients. This is a finding of a recent study presented at the Congress of the European Academy of Neurology in Lisbon. Thrombectomy can also help very old patients age 80 and over to achieve a life free of disabilities following a stroke. But the risks involved are considerable.

Full article –> here

 

JUNE 17, 2018

Latest developments in stroke treatment

From a combination of clopidogrel and aspirin that helps reduce the risk of recurrent stroke, to why the current position on the use of thrombolysis in acute stroke treatment may need revisiting: the Congress of the European Academy of Neurology in Lisbon has a major focus on the prevention and treatment of strokes.

Full article –> here

 

Dementia prevention: physical activity, big data and genetics

Physical activity plays an important part in dementia prevention. In order to identify risk factors for this neurological disease more effectively, scientists will increasingly focus on big data and genetic research, experts reported at the Congress of the European Academy of Neurology in Lisbon.

Full article –> here

 

New EAN guideline on palliative care of patients with severe multiple sclerosis: more than 900 patients and caregivers contributed

The European Academy of Neurology has developed a new guideline on palliative care of patients with severe multiple sclerosis. MS patients and caregivers have been closely involved in these efforts, experts reported at the Congress of the European Academy of Neurology in Lisbon.

Full article –> here

More than 30 million sick days per year and costs in the billions: migraines weigh heavily on careers, economies and budgets

Migraines pose a serious social burden for sufferers, the public purse and the wider economy. This was the conclusion drawn by two new studies presented at the Congress of the European Academy of Neurology in Lisbon. Depression and anxiety are leading to increased absenteeism in the workplace. Experts are calling for more investment in migraine research.

Full article –> here

 

JUNE 16, 2018

Immigration and flight: challenges and potential insights for neurology

Treating neurological diseases in immigrants poses a major challenge for European healthcare systems. But studies involving immigrants are also bringing new insights for neurological researchers regarding possible risk factors for diseases such as multiple sclerosis and stroke, experts reported at the Congress of the European Academy of Neurology in Lisbon.

Full article –> here

 

Sleep disorders: alarm signals for the early detection of neuroimmunological diseases

Sleep disorders are often the first sign of serious neurological diseases. Neurologists should inquire extensively about the quality of their patients’ sleep. This point was emphasized by experts at the Congress of the European Academy of Neurology in Lisbon. In rare neuroimmunological diseases sleep and wakefulness also frequently play an important role.

Full article –> here

 

Gender differences in the course of Parkinson’s disease

Not only do women appear to be better protected than men from Parkinson’s disease, the associated pathophysiology also shows gender differences. This is a finding of a study from Slovenia, presented at the Congress of the European Academy of Neurology in Lisbon.

Full article –> here

 

Multiple sclerosis: innovative drugs and new European treatment guideline optimise therapy and improve prognosis

MS is the most common neurological disease in young adults. There are about 2.3 million people worldwide who face a high risk of ever worsening disabilities from this disease. This year, two innovative drugs were approved in the EU, namely, cladribine, an active agent originally used in cancer therapy, and the monoclonal antibody ocrelizumab. This marks the approval of the first drug for combating primary chronic progressive MS, a form of the disease characterized by continuously worsening symptoms from the onset. In parallel to that and at the initiative of EAN and ECTRIMS, neurologists from 13 countries drew up recommendations for MS treatment in Europe. The new treatment guideline supports physicians in weighing the opportunities and risks of the available treatment options when making therapy decisions.

Full article –> here

SIGN UP FOR OUR MAILING LIST

Open Access, for medical professionals: Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified. 

We may infrequently send you news from our sponsors which is relevant to the field of neurology, but you can opt out at any time.

See a sample email newsletter here
This website is for medical professionals only.